A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer

Trial Profile

A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Pictrelisib (Primary) ; Cisplatin
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TBCRC028
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Aug 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 02 Jun 2014 The study protocol presented at 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top